Fu-Hui Zhang1, Hong-Yue Ren2, Jin-Xing Shen3, Xiao-Yun Zhang3, Hui-Ming Ye4, Dong-Yan Shen5. 1. Xiamen Maternity and Child Health Care Hospital, Xiamen 361003, Fujian Province, China. 2. Department of Pathology, The Affiliated Southeast Hospital of Xiamen University, Zhangzhou 363000, Fujian Province, China. 3. Biobank, The First Affiliated Hospital of Xiamen University, Xiamen 361003, Fujian Province, China. 4. Xiamen Maternity and Child Health Care Hospital, Xiamen 361003, Fujian Province, China. Electronic address: yehuiming@xmu.edu.cn. 5. Biobank, The First Affiliated Hospital of Xiamen University, Xiamen 361003, Fujian Province, China. Electronic address: shendongyan@163.com.
Abstract
BACKGROUND: Magnolol has shown the potential anticancer properties against a variety of cancers. However, the role of magnolol in cholangiocarcinoma (CCA) cells is unknown. In this study, we assessed the effect of magnolol on the CCA cells. METHODS: CCA cells were treated with magnolol in the absence or presence of TNFα, the activator for NF-κB. After co-incubation with magnolol, cell proliferation and growth were examined by MTT, colony formation and xenograft tumors; cell cycle was analyzed by flow cytometry; cell migration and invasion were detected by wound healing and transwell assays; the expression of PCNA, Ki67, CyclinD1, MMP-2, MMP-7 and MMP-9 and NF-κB pathway were evaluated by using Western blot. RESULTS: Magnolol inhibited the abilities of CCA cell growth, migration and invasion accompanying with a decreased expression of PCNA, Ki67, MMP-2, MMP-7 and MMP-9 (all P<0.05). TREATMENT: with magnolol induced cell cycle arrest in G1 phase with a downregulation of cell cycle protein CyclinD1 (all P<0.05). In addition, magnolol suppressed the expression of p-IκBα and p-P65 and the effect of magnolol on CCA cells could be inhibited by TNFα. CONCLUSIONS: Magnolol could inhibit the growth, migration and invasion of CCA cells through regulation of NF-κB pathway, and these data indicate that magnolol is a potential candidate for treating of CCA.
BACKGROUND:Magnolol has shown the potential anticancer properties against a variety of cancers. However, the role of magnolol in cholangiocarcinoma (CCA) cells is unknown. In this study, we assessed the effect of magnolol on the CCA cells. METHODS: CCA cells were treated with magnolol in the absence or presence of TNFα, the activator for NF-κB. After co-incubation with magnolol, cell proliferation and growth were examined by MTT, colony formation and xenograft tumors; cell cycle was analyzed by flow cytometry; cell migration and invasion were detected by wound healing and transwell assays; the expression of PCNA, Ki67, CyclinD1, MMP-2, MMP-7 and MMP-9 and NF-κB pathway were evaluated by using Western blot. RESULTS:Magnolol inhibited the abilities of CCA cell growth, migration and invasion accompanying with a decreased expression of PCNA, Ki67, MMP-2, MMP-7 and MMP-9 (all P<0.05). TREATMENT: with magnolol induced cell cycle arrest in G1 phase with a downregulation of cell cycle protein CyclinD1 (all P<0.05). In addition, magnolol suppressed the expression of p-IκBα and p-P65 and the effect of magnolol on CCA cells could be inhibited by TNFα. CONCLUSIONS:Magnolol could inhibit the growth, migration and invasion of CCA cells through regulation of NF-κB pathway, and these data indicate that magnolol is a potential candidate for treating of CCA.
Authors: Sheng-Peng Liu; Lei Huang; Jerry Flores; Yan Ding; Peng Li; Jun Peng; Gang Zuo; John H Zhang; Jun Lu; Ji-Ping Tang Journal: CNS Neurosci Ther Date: 2019-04-24 Impact factor: 5.243
Authors: Shuo Chen; Jiaqi Shen; Jing Zhao; Jiazhong Wang; Tao Shan; Junhui Li; Meng Xu; Xi Chen; Yang Liu; Gang Cao Journal: Front Oncol Date: 2020-12-02 Impact factor: 6.244